Advertisement
U.S. Markets close in 5 hrs 2 mins

CombiGene AB (publ) (COMBI.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
2.3800-0.0800 (-3.25%)
As of 03:19PM CEST. Market open.

CombiGene AB (publ)

Agavagen 52A
Lidingö 181 55
Sweden
46 8 35 73 55
https://www.combigene.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 10

Key Executives

NameTitlePayExercisedYear Born
Mr. Peter EkolindChief Executive Officer893.49kN/A1964
Associate Prof. David WoldbyeScientific FounderN/AN/A1963
Prof. Merab Kokaia Ph.D.Scientific FounderN/AN/A1956
Ms. Louise AspenbergChief Financial OfficerN/AN/A1976
Ms. Annika EricsonChief Scientific OfficerN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden.

Corporate Governance

CombiGene AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.